340 related articles for article (PubMed ID: 30541960)
1. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Kou Y; Yang R; Wang Q
J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
[TBL] [Abstract][Full Text] [Related]
2. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
3. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract][Full Text] [Related]
4. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
[TBL] [Abstract][Full Text] [Related]
5. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
6. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
7. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
8. [Translational research and diagnosis in GIST].
Wardelmann E
Pathologe; 2012 Nov; 33 Suppl 2():273-7. PubMed ID: 22968735
[TBL] [Abstract][Full Text] [Related]
9. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
10. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
11. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.
Hedenström P; Nilsson B; Demir A; Andersson C; Enlund F; Nilsson O; Sadik R
World J Gastroenterol; 2017 Aug; 23(32):5925-5935. PubMed ID: 28932084
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
13. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
[TBL] [Abstract][Full Text] [Related]
14. The rs17084733 variant in the
Ravegnini G; Serrano C; Simeon V; Sammarini G; Nannini M; Roversi E; Urbini M; Ferrè F; Ricci R; Tarantino G; Pantaleo MA; Hrelia P; Angelini S
Epigenetics; 2019 Jun; 14(6):545-557. PubMed ID: 30983504
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Hompland I; Hølmebakk T; Boye K; Stoldt S; Bjerkehagen B; Berner JM; Wiedswang AM; Revheim ME; Poulsen JP; Hall KS; Bruland ØS
Tidsskr Nor Laegeforen; 2018 Oct; 138(15):. PubMed ID: 30277049
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors: A multidisciplinary challenge.
Sanchez-Hidalgo JM; Duran-Martinez M; Molero-Payan R; Rufian-Peña S; Arjona-Sanchez A; Casado-Adam A; Cosano-Alvarez A; Briceño-Delgado J
World J Gastroenterol; 2018 May; 24(18):1925-1941. PubMed ID: 29760538
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.
Qiu C; Feng YD; Yang X
Curr Med Sci; 2023 Oct; 43(5):935-946. PubMed ID: 37828372
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of microRNAs in gastrointestinal stromal tumors revealed by high throughput quantitative RT-PCR microarray.
Tong HX; Zhou YH; Hou YY; Zhang Y; Huang Y; Xie B; Wang JY; Jiang Q; He JY; Shao YB; Han WM; Tan RY; Zhu J; Lu WQ
World J Gastroenterol; 2015 May; 21(19):5843-55. PubMed ID: 26019448
[TBL] [Abstract][Full Text] [Related]
20. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
